Clinical trial
Carboplatin and Temozolomide in Treating Patients With Unresectable or…
NCT00003747 · Mount Vernon Cancer Centre at Mount Vernon Hospital, Other · Unknown status
Key facts
| NCT number | NCT00003747 |
|---|---|
| Title | Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma |
| Official title | Phase I (Tumour Site Specific) Study of Carboplatin and Temozolomide in Patients With Advanced Melanoma |
| Lead sponsor | Mount Vernon Cancer Centre at Mount Vernon Hospital, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | carboplatin, temozolomide |
| Enrollment | 30 |
| Start date | Oct 1, 1998 |
| First posted | May 21, 2004 |
| Last update posted | Sep 20, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: